BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 24853101)

  • 1. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
    Kim KH; Roberts CW
    Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
    Darr J; Klochendler A; Isaac S; Geiger T; Eden A
    Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.
    Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW
    Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
    Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
    Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.
    McKenna ES; Tamayo P; Cho YJ; Tillman EJ; Mora-Blanco EL; Sansam CG; Koellhoffer EC; Pomeroy SL; Roberts CW
    Cell Cycle; 2012 May; 11(10):1956-65. PubMed ID: 22544318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
    Kuwahara Y; Wei D; Durand J; Weissman BE
    Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
    Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
    Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rhabdoid tumors: an initial clue to the role of chromatin remodeling in cancer.
    Lee RS; Roberts CW
    Brain Pathol; 2013 Mar; 23(2):200-5. PubMed ID: 23432645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
    Caramel J; Medjkane S; Quignon F; Delattre O
    Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdoid tumors: integrating biological insights with clinical success: a report from the SMARCB1 and Rhabdoid Tumor Symposium, Paris, December 12-14, 2013.
    Bourdeaut F; Chi SN; Frühwald MC
    Cancer Genet; 2014 Sep; 207(9):346-51. PubMed ID: 25468731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromatin remodeling: from transcription to cancer.
    Yaniv M
    Cancer Genet; 2014 Sep; 207(9):352-7. PubMed ID: 24825771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent insights into the SWI/SNF complex and the molecular mechanism of hSNF5 deficiency in rhabdoid tumors.
    Kuwahara Y; Iehara T; Matsumoto A; Okuda T
    Cancer Med; 2023 Aug; 12(15):16323-16336. PubMed ID: 37317642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
    Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
    Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB).
    Bartelheim K; Sumerauer D; Behrends U; Kodetova D; Kucera F; Leuschner I; Neumayer P; Oyen F; Rübe C; Siebert R; Schneppenheim R; Seeringer A; Vasovcak P; Frühwald MC
    Cancer Genet; 2014 Sep; 207(9):379-83. PubMed ID: 24972932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SWI/SNF complex-deficient soft tissue neoplasms: An update.
    Schaefer IM; Hornick JL
    Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAFfling pathologies: Alterations of BAF complexes in cancer.
    Arnaud O; Le Loarer F; Tirode F
    Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhabdoid tumor predisposition syndrome.
    Sredni ST; Tomita T
    Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex.
    Sen P; Luo J; Hada A; Hailu SG; Dechassa ML; Persinger J; Brahma S; Paul S; Ranish J; Bartholomew B
    Cell Rep; 2017 Feb; 18(9):2135-2147. PubMed ID: 28249160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
    Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
    Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chromatin remodeling defects and cancer: the SWI/SNF example].
    Bourdeaut F; Bièche I
    Bull Cancer; 2012 Dec; 99(12):1133-40. PubMed ID: 23222069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.